Study of two drugs with radiation for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of prostate cancer that is considered very high-risk, meaning the cancer has features like a large tumor size or high Gleason scores.
- You are at least 18 years old.
- Your testosterone level is above 50 ng/dL within the last 3 months.
- You have good kidney and liver function based on standard blood tests.
- You are able to lie still for MRI scans and undergo radiation therapy planning.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This trial tests a combination of two oral drugs, relugolix and enzalutamide, in men with high-risk prostate cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help control the cancer before or alongside local therapies like surgery or radiation.
This trial tests a new hormone pill called relugolix combined with radiation therapy for men with high-risk prostate cancer. The goal is to see if this combination improves treatment outcomes.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.